EU/3/02/116 - orphan designation for treatment of renal-cell carcinoma

autologous Renal Cell Tumour Vaccine
OrphanHuman

Overview

On 21 October 2002, orphan designation (EU/3/02/116) was granted by the European Commission to Liponova GmbH, Germany, for autologous renal tumour vaccine for the treatment of renal cell carcinoma.

EU/3/02/116: Public summary of positive opinion for orphan designation of autologous renal tumour vaccine for the treatment of renal cell carcinoma

Adopted Reference Number: EMEA/COMP/2188/02 Rev. 1

English (EN) (124.67 KB - PDF)

First published: Last updated:
View

Key facts

Active substance
autologous Renal Cell Tumour Vaccine
Intended use
Treatment of renal-cell carcinoma
Orphan designation status
Positive
EU designation number
EU/3/02/116
Date of designation
Sponsor

LipoNova
Feodor-Lynen-STr. 23
D-30625 Hannover
Germany

EMA list of opinions on orphan medicinal product designation

EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Share this page